AtriCure provides innovative atrial fibrillation (Afib) solutions designed to produce outcomes that reduce the economic and social burden of Afib.

Biotechnology

Health Care

Pharmaceutical

AtriCure

Dr. Vini Doraiswamy is the Senior Vice President of Clinical, Regulatory, Scientific and Medical Affairs at [AtriCure](/org/atricure). Dr. Doraiswamy has over 15 years of experience in the medical device industry. Prior to joining [AtriCure](/org/atricure), they served as the Vice President of Global Clinical Operations at St. Jude Medical where they oversaw the integration of 4 divisional clinical operations groups into one global clinical operations team. Dr. Doraiswamy also has experience as a Field Clinical Engineer and Product Manager at Boston Scientific and Guidant. In their role at [AtriCure](/org/atricure), Dr. Doraiswamy is responsible for providing strategic and scientific leadership for the company’s clinical development programs.

Vini Doraiswamy earned an MBA in marketing from the Wisconsin School of Business. Vini then completed postdoctoral research in cancer biology at Washington State University. Finally, they earned a PhD in molecular biology from North Dakota State University.

Their manager is Michael H. Carrel, President & CEO. Some of their coworkers include Douglas J. Seith - Chief Operating Officer, Angela L. Wirick - Chief Financial Officer, and Karl Dahlquist - Chief Legal Officer.

Vini Doraiswamy

Ms. Groves has served as one of our directors since March 2017. Ms. Groves was most recently the Chief Executive Officer at [REVA Medical](/org/reva-medical), Inc. from September of 2015 to March 2019. Prior to joining [REVA Medical](/org/reva-medical), Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure Division of [Medtronic](/org/medtronic), a leading global medical technology company. In this position, she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. The role also allowed her to successfully acquire and integrate companies, complete numerous clinical trials, and launch novel products in the United States and worldwide. Prior to this, she was the Vice President of Quality and Regulatory for [Medtronic](/org/medtronic)’s Cardiac Rhythm Disease Management (“CRDM”) business from 2006 to 2008 and before that was Vice President and General Manager for Patient Management CRDM at [Medtronic](/org/medtronic) from 2002 to 2006. Ms. Groves holds a B.S. in Pharmacy from the [University of Florida](/org/university-of-florida) and an M.B.A. from Harvard Graduate School of Business Administration. As a seasoned executive in the medical device industry, Ms. Groves has significant leadership experience managing growing businesses, achieving sustainable revenue growth, driving operational improvements and managing quality and regulatory (including FDA) matters which the Board considers as valuable skills for evaluating and improving the Company’s competitive position.

Regina E. Groves

Mr. Drake has served as one of our directors since September 2013 and as Chairman of the Board since May 2018. Mr. Drake currently serves as the President and Chief Executive Officer of [ViewRay](/org/viewray), a publicly-held medical device company with global operations in radiation therapy and imaging technologies. Mr. Drake was most recently the President and Chief Executive Officer of Spectranetics Corporation from 2011 to 2017. Spectranetics, acquired by Philips in August of 2017, developed, manufactured and distributed single-use medical devices used in minimally invasive procedures within the cardiovascular system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice President, Operations of DaVita, Inc., a leading U.S. provider of kidney care and dialysis. Previously, Mr. Drake spent 17 years in several positions within numerous healthcare business units at Covidien. From 2006 to 2009, he was President of Covidien’s Respiratory and Monitoring Solutions Global Business Unit, a $1.5 billion business with 8,000 employees. He has also served on the Board of Directors for The Zayo Group Holdings, Inc., since November 2018. Mr. Drake is the Chairperson of the [AdvaMed](/org/advamed) Radiation Therapy Sector and a board member for the Medical Device Manufacturers Association (MDMA). Mr. Drake holds a B.S. in Business Administration from Miami University of Ohio. Mr. Drake’s significant leadership experience in the medical device industry provides him insight into the high-level corporate governance, executive compensation, regulatory (including FDA) and business management matters that the Company and the Board consider on a regular basis and gives him skills which the Board considers as valuable for evaluating and improving the Company’s competitive position and serving as Chairman of the Board of Directors. 

Scott W. Drake

Mr. Lanning has served as one of our directors since February 2006. Mr. Lanning currently is a financial consultant and a principal with the Lanning CPA group. Most recently Mr. Lanning served as Vice President-Finance and Chief Financial Officer of Frisch’s Restaurants for over 5 years. Prior to joining Frisch’s, Mr. Lanning served as Vice President, Investor Relations and Treasurer of [Hillenbrand](/org/hillenbrand), Inc., Hill-Rom, Inc. and [Hillenbrand](/org/hillenbrand) Industries, diversified leaders in the healthcare equipment, funeral services, and material handling industries. Prior to joining [Hillenbrand](/org/hillenbrand) in 1988, Mr. Lanning spent twelve years in various accounting positions with Ernst & Whinney (now EY). Mr. Lanning, a Certified Public Accountant and a Chartered Global Management Accountant, is presently a member of the American Institute of CPAs (AICPA). In addition, he is a past Chairman and Board member of the Indiana CPA Society and has served on the boards of several charitable and educational institutions over the years. Mr. Lanning received his B.S. in Accounting from [Ball State University](/org/ball-state-university). As a certified public accountant, Mr. Lanning developed significant experience in preparing, auditing, analyzing and evaluating financial statements and dealt with broad and complex accounting issues comparable to those of the Company, which qualifies him as an “audit committee financial expert” under SEC rules. 

Mark R. Lanning

Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at [Henry Schein](/org/henry-schein) (Nasdaq: HSIC) and a member of the Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at [Henry Schein](/org/henry-schein), she led the Urology and Pelvic Health business for Boston Scientific, Inc. (NYSE: BSX) and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company (NYSE: JNJ). In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies.

Karen Prange

Michael H. Carrel has served as President and Chief Executive Officer of [AtriCure](/org/atricure) (NASDAQ: ATRC) since November 2012. [AtriCure](/org/atricure), Inc. is a medical device company that provides innovative solutions for the treatment of atrial fibrillation (Afib) and related conditions. [AtriCure](/org/atricure)’s mission is to reduce the global Afib epidemic and heal the lives of those affected.

Since joining [AtriCure](/org/atricure), Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science, and education. This strategic approach has led [AtriCure](/org/atricure) to significantly invest in groundbreaking clinical trials for the treatment of Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 600 employees. In addition, during Mike’s tenure, [AtriCure](/org/atricure) has acquired two companies, Estech and nContact, adding leading ablation technologies to further [AtriCure](/org/atricure)’s market position worldwide.

His 24-year career includes successful leadership in global organizations in the healthcare and technology industries. Before joining [AtriCure](/org/atricure), Mr. Carrel was President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company. He led Vital Images to a global leadership position in the healthcare and medical software industry. Under his leadership, the company grew revenue and profitability, increased global market share, expanded its presence to over 90 countries, and lead the company through a sale to Toshiba Medical Systems Corporation. Prior to joining Vital Images, Mike was President and CEO of Zamba Corp., a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems.

Mr. Carrel serves on the Board of Medical Device Manufacturers Association (MDMA) and [Axonics](/org/axonics) Modulation Technologies, Inc. He earned a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Michael H. Carrel

Angela L. Wirick, C.P.A. was appointed Chief Financial Officer in August 2020. Immediately prior to this, Ms. Wirick served as [AtriCure](/org/atricure)’s Vice President, Finance for four years, where she led the global accounting and finance functions of the company and supported strategic projects. Ms. Wirick joined [AtriCure](/org/atricure) in 2014 as Director, Finance, overseeing financial planning, analysis and SEC reporting. Ms. Wirick began her career in public accounting at Arthur Andersen LLP and Deloitte & Touche LLP, serving clients in a variety of industries in Cincinnati, Ohio. Ms. Wirick received her B.S.B.A. in Accounting from the [University of Dayton](/org/university-of-dayton), and is a Certified Public Accountant.

Angela L. Wirick

Justin Noznesky

Ms. Johnson has served as one of our directors since March 2017. Ms. Johnson is currently President of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States, a position she has held since 2000. Prior to her role at Affinity, Johnson was employed for 17 years at [Medtronic](/org/medtronic), serving most recently as senior vice president and chief administrative officer from 1998 to 1999. Her experience at [Medtronic](/org/medtronic) also includes service as President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business, among other roles. In addition to her role at Affinity, Ms. Johnson currently serves on the Board of Directors of [Piper Jaffray](/org/piper-jaffray) (NYSE: PJC) and Chair of the Investment Advisory Board of the University of Minnesota Foundation and on the boards of several private entities. Her previous public board experience includes service on the Board of Directors of Spectranetics Corporation, which was acquired by Philips, ADC Telecommunications, which was acquired by Tyco Electronics, and [Pentair](/org/pentair). Ms. Johnson received her B.A. from St. Olaf College. Ms. Johnson brings extensive knowledge of health care and medical technology industries to the Board as well as broad experience in finance and corporate governance.

B. Kristine Johnson

Mr. Collar has served as one of our directors since February 2008. Mr. Collar retired in 2008 as an officer within the Procter and Gamble Company where his roles included President of the Global Pharmaceuticals and Personal Health business. Mr. Collar joined Procter and Gamble in 1975 as a sales representative, then moved into advertising, and subsequently assumed roles of progressive responsibility within the Health and Personal Care, Beauty Care, New Business Development, Pharmaceuticals and Personal Health Care Products divisions over his 32-year career. Mr. Collar, who now owns his own investment and consulting business, was a director of First Financial Bancorp, a publicly-held bank holding company and [Enable Injections](/org/enable-injections), a start-up company focusing on high volume injection devices for biologic drugs and serves in director and advisory roles in several philanthropic, academic and economic development organizations. Mr. Collar received his B.S. from [Northern Illinois University](/org/northern-illinois-university). Mr. Collar’s experience as a public company executive and board member provides him insight into high-level corporate governance and business management matters which the Board considers on a regular basis.

Mark A. Collar

Mr. White has served as one of our directors since March 2013. Most recently, Mr. White served as President and Chief Operating Officer of Entellus Medical. Entellus Medical, which was acquired by Stryker Corporation in February 2018, was a publicly-traded company that delivered innovative, high quality, minimally invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by [Medtronic](/org/medtronic), Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several positions with [Medtronic](/org/medtronic), Inc. Mr. White served as President of [Medtronic](/org/medtronic) Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with [Medtronic](/org/medtronic), Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University. Mr. White’s significant knowledge of the medical device industry and experience in growing companies commercially uniquely benefit AtriCure and enhance its capacities in business development initiatives.

Robert S. White

Douglas J. Seith

Tonya Austin

Karl Dahlquist

Sam Privitera is the current Chief Technology Officer at [AtriCure](/org/atricure). Sam has held this position since 2012. Prior to that, they were the VP Research, Engineering, IP and Business Development at [AtriCure](/org/atricure) from 2003-2012. Sam was also the Group Director, R&D at Ethicon Endo-Surgery from 1990-2003. Sam started their engineering career as a Plastics Engineer at Fisher Price from 1988-1990.

Sam Privitera has a J.D. from Northern Kentucky University—Salmon P. Chase College of Law, and an M.B.A. in marketing from [Xavier University](/org/xavier-university). Sam also has a BS in mechanical engineering from the [University at Buffalo](/org/university-at-buffalo).

Sam Privitera reports to Michael H. Carrel, President & CEO. They are on a team with Douglas J. Seith - Chief Operating Officer, Tonya Austin - CHRO, and Justin Noznesky - Chief Marketing and Strategy Officer.

Sam Privitera

Mr. Florin is currently Executive Vice President at Zimmer Biomet Holdings (NYSE: ZBH), a global leader in musculoskeletal healthcare. He was appointed to this position in July 2019 upon announcing his intention to retire from the company. Previously, he served as Executive Vice President and Chief Financial Officer of the company. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet Holdings, Mr. Florin was Chief Financial Officer for Biomet, Inc. until the company merged with Zimmer, Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP.

Daniel Florin

Sven A. Wehrwein has served on our board of directors since November 2016. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. During his more than 35 years in accounting and finance, Mr. Wehrwein has experience as an investment banker to emerging-growth companies, chief financial officer, and certified public accountant (inactive). Wehrwein currently serves on the boards of several companies, including Proto Labs, Inc. and SPS Commerce, Inc. In addition, he has served as a Director for a number of other medical device and high growth companies including tenures on the boards of Cogentix Medical, Inc., Compellent Technologies Inc., Synovis Life Technologies, Inc., and Vital Images. Mr. Wehrwein holds a B.S. in Business from Loyola University of Chicago and an M.S. in Management from the Sloan School, MIT. Mr. Wehrwein brings capabilities in financial understanding, strategic planning and auditing to the Board, given his experiences in investment banking and financial leadership positions. Mr. Wehrwein qualifies as an “audit committee financial expert” under SEC rules.

AtriCure

About

Photos

Values

Insider experiences

Org chart

Teams

Jobs

Wires

Similar organizations